Table 2. The majority of metastatic non-small cell lung cancers are RHAMM-positive.
ID | RHAMM | Type | Metastatic site |
---|---|---|---|
922 | + | Adenocarcinoma | Bone |
927 | + | Adenocarcinoma | Brain |
928 | + | NSCLC, NOS | Brain |
929 | − | Adenocarcinoma | Brain |
930 | + | NSCLC, NOS | Brain |
931 | + | NSCLC, NOS | Bone |
932 | + | Adenocarcinoma | Brain |
934 | + | NSCLC, NOS | Brain |
935 | + | Squamous cell carcinoma | Brain |
939 | + | Adenocarcinoma | Brain |
940 | + | Adenocarcinoma | Brain |
947 | + | Adenocarcinoma | Brain |
949 | + | Squamous cell carcinoma | Brain |
951 | + | Adenocarcinoma | Brain |
954 | + | Adenocarcinoma | Brain |
956 | + | Adenocarcinoma | Brain |
963 | + | Adenocarcinoma | Brain |
964 | + | Adenocarcinoma | Brain |
965 | + | Adenocarcinoma | Brain |
966 | + | Adenocarcinoma | Brain |
968 | + | Adenocarcinoma | Brain |
969 | + | Adenocarcinoma | Brain |
970 | + | Adenocarcinoma | Bone |
NOS: not otherwise specified.